© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma | Clinical
FDA Lifts Partial Clinical Hold from the MELANI-1 Study in Multiple Myeloma
November 18, 2020
The partial clinical hold placed by the FDA on the phase 1 chimeric antigen receptor T-cell clinical trial, MELANI-01, has now been lifted.
Application for Subcutaneous Daratumumab Regimen Submitted to FDA, EMA Seeking Approval in R/R Myeloma
November 12, 2020
Regulatory applications have been submitted to the FDA and European Medicines Agency seeking approval of a subcutaneous form of daratumumab in combination with pomalidomide and dexamethasone as treatment of patients with relapsed or refractory multiple myeloma who have received at least 1 previous therapy.
Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?
October 29, 2020
Shaji K. Kumar, MD, addresses an important unanswered question that remains in the treatment landscape of newly diagnosed multiple myeloma, which is whether 3- or 4-drug regimens should be used in the frontline setting.
MYC Status Relevant to Risk Stratification in Newly Diagnosed Multiple Myeloma
October 29, 2020
In evaluating MYC rearrangement and its correlation with disease burden and prognostics in newly diagnosed multiple myeloma, a group of Mayo Clinic investigators found that the alteration is associated with high disease burden and independently prognosticates adverse outcomes in patients.
Progression-Free Survival Improved With Daratumumab in Phase 3 CASSIOPEIA Study of Myeloma
October 22, 2020
The phase 3 CASSIOPEIA study met its primary end point of progression-free survival with daratumumab maintenance in newly-diagnosed multiple myeloma eligible for autologous stem cell transplant.
Multiple Myeloma Treatment Paradigm Improved Markedly In Recent Years
October 13, 2020
Kenneth C. Anderson, MD, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.
Optimal Strategies for Treatment of Multiple Myeloma in Newly Diagnosed Patients
October 11, 2020
During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.
Expert Reviews New Diagnostic and Staging Criteria in Multiple Myeloma
October 11, 2020
In an interview with Targeted Oncology, Jens Hillengass, MD, shared his insights on the latest edition of the diagnostic and staging criteria for multiple myeloma that have become standard now for the management of these patients.
Mejia-Garcia Provides Rationale for Using Daratumumab in Multiple Myeloma
October 03, 2020
During a Targeted Oncology Case Based Peer Perspective event, Alex Mejia-Garcia, MD, discussed the case of a 51-year-old male patient with stage II multiple myeloma.
FDA Grants Priority Review to Ide-Cel for Relapsed/Refractory Multiple Myeloma
September 22, 2020
The FDA granted a Priority Review designation to idecabtagene vicleucel as treatment of adult patients with multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.